Literature DB >> 20214410

Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model.

Mariska Y M Peeters1, Karel Allegaert, Heleen J Blussé van Oud-Alblas, Massimo Cella, Dick Tibboel, Meindert Danhof, Catherijne A J Knibbe.   

Abstract

For propofol clearance, allometric scaling has been applied successfully for extrapolations between species (rats and humans) and within the human bodyweight range (children and adults). In this analysis, the human bodyweight range is explored to determine for which range an allometric model with a fixed or estimated exponent can be used to predict propofol clearance, without correction for maturation. The predictive value of the allometric equation, clearance (CL) is equal to 0.071 x bodyweight in kg0.78, which was developed from rats, children and adults, and the predictive value of a fixed exponent allometric model derived from the basal metabolic rate, CL is equal to CL standardized to a 70 kg adult x (bodyweight in kg standardized to a 70 kg adult)0.75, were evaluated across five independent patient groups including (i) 25 (pre)term neonates with a postmenstrual age of 27-43 weeks; (ii) 22 postoperative infants aged 4-18 months; (iii) 12 toddlers aged 1-3 years; (iv) 14 adolescents aged 10-20 years; and (v) 26 critically ill adults sedated long term. The median percentage error of the predictions was calculated using the equation %error = (CL(allometric) - CL(i))/CL(i) x 100, where CL(allometric) is the predicted propofol clearance from the allometric equations for each individual and CL(i) is the individual-predicted (post hoc) propofol clearance value derived from published population pharmacokinetic models. In neonates, the allometric model developed from rats, children and adults, and the fixed-exponent allometric model, systematically overpredicted individual propofol clearance, with median percentage errors of 288% and 216%, respectively, whereas in infants, both models systematically underpredicted individual propofol clearance, with median percentage errors of -43% and -55%, respectively. In toddlers, adolescents and adults, both models performed reasonably well, with median percentage errors of -12% and -32%, respectively, in toddlers, 16% and -14%, respectively, in adolescents, and 12% and -18%, respectively, in adults. Both allometric models based on bodyweight alone may be of use to predict propofol clearance in individuals older than 2 years. Approaches that also incorporate maturation are required to predict clearance under the age of 2 years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214410     DOI: 10.2165/11319350-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  20 in total

1.  Allometric exponents do not support a universal metabolic allometry.

Authors:  Craig R White; Phillip Cassey; Tim M Blackburn
Journal:  Ecology       Date:  2007-02       Impact factor: 5.499

2.  Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates.

Authors:  Gary C Packard; Geoffrey F Birchard
Journal:  J Exp Biol       Date:  2008-11       Impact factor: 3.312

3.  A size standard for pharmacokinetics.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

4.  Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.

Authors:  E H Cox; C A Knibbe; V S Koster; M W Langemeijer; E E Tukker; R Lange; P F Kuks; H J Langemeijer; L Lie-A-Huen; M Danhof
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

5.  Population pharmacokinetics of propofol: a multicenter study.

Authors:  J Schüttler; H Ihmsen
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

6.  Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.

Authors:  Brian J Anderson; Gerard Pons; Elisabeth Autret-Leca; Karel Allegaert; Eric Boccard
Journal:  Paediatr Anaesth       Date:  2005-04       Impact factor: 2.556

7.  Allometric relationships between the pharmacokinetics of propofol in rats, children and adults.

Authors:  Catherijne A J Knibbe; Klaas P Zuideveld; Leon P H J Aarts; Paul F M Kuks; Meindert Danhof
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

8.  Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients.

Authors:  M Y M Peeters; L J Bras; J DeJongh; R M J Wesselink; L P H J Aarts; M Danhof; C A J Knibbe
Journal:  Clin Pharmacol Ther       Date:  2007-08-08       Impact factor: 6.875

9.  Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery.

Authors:  Catherijne A J Knibbe; Gitte Melenhorst-de Jong; Maaike Mestrom; Carin M A Rademaker; Allart F A Reijnvaan; Klaas P Zuideveld; Paul F M Kuks; Hans van Vught; Meindert Danhof
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

10.  Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial.

Authors:  K J S Anand; B J Anderson; N H G Holford; R W Hall; T Young; B Shephard; N S Desai; B A Barton
Journal:  Br J Anaesth       Date:  2008-08-23       Impact factor: 9.166

View more
  23 in total

1.  Obesity and allometric scaling of pharmacokinetics.

Authors:  Douglas J Eleveld; Johannes H Proost; Anthony R Absalom; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

2.  Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Authors:  Caroline Petit; Vincent Jullien; Adeline Samson; Jérémie Guedj; Jean-René Kiechel; Sarah Zohar; Emmanuelle Comets
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

Authors:  Chenguang Wang; Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

4.  Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusions.

Authors:  Johan Francois Coetzee
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

5.  Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects : An Allometric Approach.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

Review 6.  Dosage individualization in children: integration of pharmacometrics in clinical practice.

Authors:  Wei Zhao; Stéphanie Leroux; Evelyne Jacqz-Aigrain
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

Review 7.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

8.  Prediction of drug clearance in children: an evaluation of the predictive performance of several models.

Authors:  Iftekhar Mahmood; Carl-Michael Staschen; Kosalaram Goteti
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

9.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

10.  Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Xi-Wen Li; Zheng Jiao; Jin Zhang; Xin Rao; Da-Yong Zeng; Xin-Hua Lin; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2018-11-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.